593 related articles for article (PubMed ID: 25881872)
41. Piperacillin concentration in relation to therapeutic range in critically ill patients--a prospective observational study.
Zander J; Döbbeler G; Nagel D; Maier B; Scharf C; Huseyn-Zada M; Jung J; Frey L; Vogeser M; Zoller M
Crit Care; 2016 Apr; 20():79. PubMed ID: 27039986
[TBL] [Abstract][Full Text] [Related]
42. Extended versus bolus infusion of meropenem and piperacillin: a pharmacokinetic analysis.
De Waele J; Carlier M; Hoste E; Depuydt P; Decruyenaere J; Wallis SC; Lipman J; Roberts JA
Minerva Anestesiol; 2014 Dec; 80(12):1302-9. PubMed ID: 24762706
[TBL] [Abstract][Full Text] [Related]
43. Continuous Infusion of Piperacillin/Tazobactam and Meropenem in ICU Patients Without Renal Dysfunction: Are Patients at Risk of Underexposure?
Esteve-Pitarch E; Gumucio-Sanguino VD; Cobo-Sacristán S; Shaw E; Maisterra-Santos K; Sabater-Riera J; Pérez-Fernandez XL; Rigo-Bonnin R; Tubau-Quintano F; Carratalà J; Colom-Codina H; Padullés-Zamora A
Eur J Drug Metab Pharmacokinet; 2021 Jul; 46(4):527-538. PubMed ID: 34131869
[TBL] [Abstract][Full Text] [Related]
44. OTAC: Optimization of Antibiotic Therapy in Critically ill Patients. Using beta-lactam antibiotics by continuous infusion.
Esteve-Pitarch E; Padullés-Zamora A; Maisterra-Santos K; Colom-Codina H; Cobo-Sacristán S
Farm Hosp; 2019 Sep; 43(5):151-157. PubMed ID: 31469627
[TBL] [Abstract][Full Text] [Related]
45. Pharmacokinetics and Pharmacodynamics of Linezolid in Patients With Sepsis Receiving Continuous Venovenous Hemofiltration and Extended Daily Hemofiltration.
Zheng J; Sun Z; Sun L; Zhang X; Hou G; Han Q; Li X; Liu G; Gao Y; Ye M; Wang H; Yu K
J Infect Dis; 2020 Mar; 221(Suppl 2):S279-S287. PubMed ID: 32176792
[TBL] [Abstract][Full Text] [Related]
46. Continuous infusion versus intermittent infusion of vancomycin in critically ill patients undergoing continuous venovenous hemofiltration: a prospective interventional study.
Xu J; Duan L; Li J; Chen F; Xu X; Lu J; Zhuang Z; Cao Y; Yuan Y; Liu X; Sun J; Zhou Q; Shi L; Tang L
BMC Infect Dis; 2022 Aug; 22(1):667. PubMed ID: 35918657
[TBL] [Abstract][Full Text] [Related]
47. Vancomycin clearance during continuous venovenous haemofiltration in critically ill patients.
Chaijamorn W; Jitsurong A; Wiwattanawongsa K; Wanakamanee U; Dandecha P
Int J Antimicrob Agents; 2011 Aug; 38(2):152-6. PubMed ID: 21636256
[TBL] [Abstract][Full Text] [Related]
48. Population pharmacokinetics and dose simulation of vancomycin in critically ill patients during high-volume haemofiltration.
Escobar L; Andresen M; Downey P; Gai MN; Regueira T; Bórquez T; Lipman J; Roberts JA
Int J Antimicrob Agents; 2014 Aug; 44(2):163-7. PubMed ID: 24837847
[TBL] [Abstract][Full Text] [Related]
49. Target attainment with continuous dosing of piperacillin/tazobactam in critical illness: a prospective observational study.
Aardema H; Nannan Panday P; Wessels M; van Hateren K; Dieperink W; Kosterink JGW; Alffenaar JW; Zijlstra JG
Int J Antimicrob Agents; 2017 Jul; 50(1):68-73. PubMed ID: 28501674
[TBL] [Abstract][Full Text] [Related]
50. Population Pharmacokinetics and Pharmacodynamics of Extended-Infusion Piperacillin and Tazobactam in Critically Ill Children.
Nichols K; Chung EK; Knoderer CA; Buenger LE; Healy DP; Dees J; Crumby AS; Kays MB
Antimicrob Agents Chemother; 2016 Jan; 60(1):522-31. PubMed ID: 26552978
[TBL] [Abstract][Full Text] [Related]
51. Dose optimization of piperacillin/tazobactam in critically ill children.
De Cock PAJG; van Dijkman SC; de Jaeger A; Willems J; Carlier M; Verstraete AG; Delanghe JR; Robays H; Vande Walle J; Della Pasqua OE; De Paepe P
J Antimicrob Chemother; 2017 Jul; 72(7):2002-2011. PubMed ID: 28387840
[TBL] [Abstract][Full Text] [Related]
52. Population pharmacokinetics of piperacillin in febrile children receiving cancer chemotherapy: the impact of body weight and target on an optimal dosing regimen.
Thorsted A; Kristoffersson AN; Maarbjerg SF; Schrøder H; Wang M; Brock B; Nielsen EI; Friberg LE
J Antimicrob Chemother; 2019 Oct; 74(10):2984-2993. PubMed ID: 31273375
[TBL] [Abstract][Full Text] [Related]
53. A protocol for a multicentre randomised controlled trial of continuous beta-lactam infusion compared with intermittent beta-lactam dosing in critically ill patients with severe sepsis: the BLING II study.
Dulhunty JM; Roberts JA; Davis JS; Webb SA; Bellomo R; Gomersall C; Shirwadkar C; Eastwood GM; Myburgh J; Paterson DL; Starr T; Udy AA; Paul SK; Lipman J; ;
Crit Care Resusc; 2013 Sep; 15(3):179-85. PubMed ID: 23944203
[TBL] [Abstract][Full Text] [Related]
54. Population Pharmacokinetics of Cefuroxime in Critically Ill Patients Receiving Continuous Venovenous Hemofiltration With Regional Citrate Anticoagulation and a Phosphate-Containing Replacement Fluid.
Janssen PK; Foudraine NA; Burgers DM; Neef K; le Noble JL
Ther Drug Monit; 2016 Dec; 38(6):699-705. PubMed ID: 27494946
[TBL] [Abstract][Full Text] [Related]
55. Clinical outcomes of extended versus intermittent administration of piperacillin/tazobactam for the treatment of hospital-acquired pneumonia: a randomized controlled trial.
Bao H; Lv Y; Wang D; Xue J; Yan Z
Eur J Clin Microbiol Infect Dis; 2017 Mar; 36(3):459-466. PubMed ID: 27796647
[TBL] [Abstract][Full Text] [Related]
56. Piperacillin pharmacokinetics and target attainment in children with cancer and fever: Can we optimize our dosing strategy?
Maarbjerg SF; Thorsted A; Kristoffersson A; Friberg LE; Nielsen EI; Wang M; Brock B; Schrøder H
Pediatr Blood Cancer; 2019 Jun; 66(6):e27654. PubMed ID: 30740885
[TBL] [Abstract][Full Text] [Related]
57. Vancomycin pharmacokinetics during high-volume continuous venovenous hemofiltration in critically ill septic patients.
Petejova N; Martinek A; Zahalkova J; Duricova J; Brozmannova H; Urbanek K; Grundmann M; Plasek J; Kacirova I
Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2014; 158(1):65-72. PubMed ID: 23132513
[TBL] [Abstract][Full Text] [Related]
58. Steady-state pharmacokinetics and pharmacodynamics of piperacillin and tazobactam administered by prolonged infusion in obese patients.
Cheatham SC; Fleming MR; Healy DP; Chung CE; Shea KM; Humphrey ML; Kays MB
Int J Antimicrob Agents; 2013 Jan; 41(1):52-6. PubMed ID: 23228881
[TBL] [Abstract][Full Text] [Related]
59. [Personalised antibiotic therapy in a surgical intensive care unit overview of current knowledge and the results of an observational kinetic study].
Kaška M; Martinková J; Havel E; Kočí J; Fousková A; Solichová D; Kujovská L; Selke-Krulichová I; Práznovec I; Salavec V
Rozhl Chir; 2014 Sep; 93(9):456-62. PubMed ID: 25301344
[TBL] [Abstract][Full Text] [Related]
60. Micafungin pharmacokinetic/pharmacodynamic adequacy for the treatment of invasive candidiasis in critically ill patients on continuous venovenous haemofiltration.
Maseda E; Grau S; Villagran MJ; Hernandez-Gancedo C; Lopez-Tofiño A; Roberts JA; Aguilar L; Luque S; Sevillano D; Gimenez MJ; Gilsanz F
J Antimicrob Chemother; 2014 Jun; 69(6):1624-32. PubMed ID: 24505092
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
